<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107197</article-id><article-id pub-id-type="publisher-id">ACM-36493</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_73140647.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  老年恶性胆道梗阻患者塑料支架阻塞物细菌学和抗生素耐药性分析
  Analysis of Bacteriology and Antibiotic Resistance of Plastic Stent Obstruction in Elderly Patients with Malignant Biliary Obstruction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孔</surname><given-names>国萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>解</surname><given-names>祥军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1298</fpage><lpage>1305</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析老年恶性胆道梗阻患者塑料支架阻塞物中细菌种类、分布特征以及药敏情况，为临床上合理选用抗生素提供参考。方法：共收集行内镜下胆道塑料支架更换的老年恶性胆道梗阻患者60例，对术中被更换的支架内腔的阻塞物行细菌培养与药敏试验，观察并分析其细菌分布特征及耐药情况。结果：60份阻塞物标本培养结果均为阳性，共分离培养出93株病原菌，革兰阴性杆菌61例(65.6%)，革兰阳性球菌30例(32.2%)，真菌2例(2.2%)。前五位细菌依次为大肠埃希菌21例(22.6%)、屎肠球菌15例(16.1%)、肺炎克雷伯菌13例(14.0%)、铜绿假单胞菌11例(11.8%)、粪肠球菌10例(10.8%)。药敏结果显示碳青霉烯类是针对革兰阴性菌最敏感的药物；屎肠球菌和粪肠球菌对亚胺培南、利奈唑胺及替考拉宁药物的敏感率高达100%，无耐药菌株产生。结论：老年恶性胆道梗阻患者支架阻塞物细菌培养阳性率高，以革兰阴性菌感染为主，肠球菌属检出率高于大肠埃希菌，经验性选用抗菌药时，应注意对革兰阴性杆菌及肠球菌属的覆盖。早期积极应用碳青霉烯类药物可以有效控制感染。无禁忌的情况下，应该及时更换支架，以便解除胆道梗阻。
    Objective: To analyze the bacterial species, distribution characteristics and drug sensitivity of plastic stent obstruction in elderly patients with malignant biliary obstruction, so as to provide reference for the rational selection of antibiotics in clinical practice. Methods: A total of 60 elderly patients with malignant biliary obstruction who had been replaced with plastic stent under endoscopy were collected. Bacterial culture and drug sensitivity test were performed on the obstruction in the stent cavity, and the bacterial distribution and drug resistance were observed and analyzed. Results: The culture results of 60 obstruction specimens were all positive. A total of 93 pathogenic bacteria were isolated and cultured, 61 cases of Gram-negative bacilli (65.6%), 30 cases of Gram- positive cocci (32.2%), and 2 cases of fungi (2.2%). The top five bacteria were 21 cases of Escherichia coli (22.6%), 15 cases of Enterococcus faecium (16.1%), 13 cases of Klebsiella pneumoniae (14.0%), and 11 cases of Pseudomonas aeruginosa (11.8%), 10 cases of Enterococcus faecalis (10.8%). Drug sensitivity results show that carbapenems are the most sensitive drugs against Gram-negative bacteria; Enterococcus faecium and Enterococcus faecalis are 100% sensitive to imipenem, linezolid, and teicoplanin, and no resistant strains were found. Conclusion: In the elderly patients with malignant biliary obstruction, the positive rate of bacterial culture of stent obstruction is high, mainly due to gram-negative bacterial infection, and the detection rate of Enterococcus is higher than that of Escherichia coli. When selecting antibacterial agents empirically, attention should be paid to the coverage of Gram-negative bacteria and Enterococcus. Early active use of carbapenems can effectively control infection. If there is no contraindication, the stent should be replaced in time to relieve biliary obstruction. 
  
 
</p></abstract><kwd-group><kwd>恶性胆道梗阻，塑料支架，细菌分布，抗生素耐药性, Malignant Biliary Obstruction</kwd><kwd> Plastic Stent</kwd><kwd> Bacterial Distribution</kwd><kwd> Antibiotic Resistance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>老年恶性胆道梗阻患者塑料支架阻塞物细菌学和抗生素耐药性分析<sup> </sup></title><p>孔国萍，解祥军</p><p>青岛大学附属青岛市市立医院，山东 青岛</p><p>收稿日期：2020年6月14日；录用日期：2020年7月7日；发布日期：2020年7月14日</p><disp-formula id="hanspub.36493-formula15"><graphic xlink:href="//html.hanspub.org/file/23-1571424x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：分析老年恶性胆道梗阻患者塑料支架阻塞物中细菌种类、分布特征以及药敏情况，为临床上合理选用抗生素提供参考。方法：共收集行内镜下胆道塑料支架更换的老年恶性胆道梗阻患者60例，对术中被更换的支架内腔的阻塞物行细菌培养与药敏试验，观察并分析其细菌分布特征及耐药情况。结果：60份阻塞物标本培养结果均为阳性，共分离培养出93株病原菌，革兰阴性杆菌61例(65.6%)，革兰阳性球菌30例(32.2%)，真菌2例(2.2%)。前五位细菌依次为大肠埃希菌21例(22.6%)、屎肠球菌15例(16.1%)、肺炎克雷伯菌13例(14.0%)、铜绿假单胞菌11例(11.8%)、粪肠球菌10例(10.8%)。药敏结果显示碳青霉烯类是针对革兰阴性菌最敏感的药物；屎肠球菌和粪肠球菌对亚胺培南、利奈唑胺及替考拉宁药物的敏感率高达100%，无耐药菌株产生。结论：老年恶性胆道梗阻患者支架阻塞物细菌培养阳性率高，以革兰阴性菌感染为主，肠球菌属检出率高于大肠埃希菌，经验性选用抗菌药时，应注意对革兰阴性杆菌及肠球菌属的覆盖。早期积极应用碳青霉烯类药物可以有效控制感染。无禁忌的情况下，应该及时更换支架，以便解除胆道梗阻。</p><p>关键词 :恶性胆道梗阻，塑料支架，细菌分布，抗生素耐药性</p><disp-formula id="hanspub.36493-formula16"><graphic xlink:href="//html.hanspub.org/file/23-1571424x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/23-1571424x7_hanspub.png" /> <img src="//html.hanspub.org/file/23-1571424x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>恶性胆道梗阻是由各种恶性肿瘤引起肝内和(或)肝外不同部位胆道狭窄或闭塞的统称。最常见于胰腺癌和胆管癌，其他病因包括胆囊癌、肝细胞癌、淋巴瘤等。临床上通常表现为腹痛、发热(体温 ≥ 38℃)、无痛性黄疸及皮肤瘙痒。常常引起梗阻性黄疸、肝功能迅速恶化，导致严重的胆系感染，病死率高。目前，对于无法通过根治性手术切除治疗的晚期恶性胆道梗阻患者，尤其是老年患者，经内镜逆行胰胆管造影术(endoscopic retrograde cholangiopancreatography, ERCP)植入胆道支架已经成为一种比较安全的、姑息性解除胆道梗阻的治疗手段 [<xref ref-type="bibr" rid="hanspub.36493-ref1">1</xref>]。胆道支架的植入，可显著改善患者的生活质量，减少胆汁淤积和皮肤瘙痒 [<xref ref-type="bibr" rid="hanspub.36493-ref2">2</xref>]。塑料胆道支架具有花费低、操作简便、发生阻塞时便于拆除和替换等优点 [<xref ref-type="bibr" rid="hanspub.36493-ref3">3</xref>]，因此，它被广泛应用于临床，目前对于胆道支架阻塞机制及阻塞成分的研究均有相关报道 [<xref ref-type="bibr" rid="hanspub.36493-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.36493-ref5">5</xref>]，其中支架阻塞物中的细菌与胆系感染密切相关，故本研究通过收集老年恶性胆道梗阻患者中塑料支架内腔阻塞物进行细菌培养及药敏试验，以了解病原菌的种类、分布特征及药物敏感性，为治疗胆系感染时抗菌药物的选择提供依据。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 病例资料</title><p>回顾性收集2018年6月至2019年12月在青岛市市立医院行ERCP胆道支架更换的老年恶性胆道梗阻患者60例，其中男性36例,女性24例，年龄为65~93岁，平均年龄(79.6 &#177; 5.7)岁；其中肝门部胆管癌34例，胰腺癌13例，壶腹癌11例，胆囊癌2例。有胆系感染者41例，无胆系感染者19例。60例患者的总胆红素平均水平为(157 &#177; 54.5) μmol/l，60例患者均在患者病情允许的情况下经ERCP行塑料支架更换并且全部更换成功。被更换出的塑料支架直径大小为8.5Fr的为56个，大小为10Fr的为4个。支架在胆道内放置的平均时间为(128.7 &#177; 52.5)天。本研究得到青岛市市立医院科研伦理委员会批准。</p></sec><sec id="s4_2"><title>2.2. 纳入标准和排除标准</title><sec id="s4_2_1"><title>2.2.1. 纳入标准</title><p>① 患者年龄均 ≥ 65岁；</p><p>② B超、CT、MRI、PET-CT等影像学检查或病理穿刺活检明确诊断为原发于胆道系统或胰腺的恶性肿瘤；</p><p>③ 不能行根治性手术切除者；</p><p>④ 预计患者生存时间 ≥ 3个月；</p><p>⑤ 无严重心、肺疾患等并发症，能较好的耐受经ERCP置入塑料支架术；</p><p>⑥ 患者及其家属同意经ERCP置入塑料支架治疗并且签署知情同意书。</p></sec><sec id="s4_2_2"><title>2.2.2. 排除标准</title><p>① 胆石症、胆道蛔虫症、胆管炎症、医源性胆道狭窄及胆管周围良性病变压迫引起的胆道梗阻；</p><p>② 合并严重心、肺疾患等并发症或严重的凝血功能障碍；</p><p>③ 存在大量顽固性腹水或肝衰；</p><p>④ 依从性差以及患有严重精神疾病不能配合；</p><p>⑤ 临床资料不全。</p></sec></sec><sec id="s4_3"><title>2.3. 细菌的培养鉴定及药敏分析</title><p>将ERCP术中被更换出的塑料支架放置于无菌培养皿中，在无菌条件下用镊子取出支架两端腔内阻塞物，肉眼观察阻塞物的颜色、质地、成分，并将阻塞物与随后冲洗支架管腔的5 ml生理盐水制成混悬液，注入需氧培养瓶中。鉴于本试验条件限制，未检测厌氧菌。将培养瓶放入BD9120培养仪(美国BD公司)中，待出现报警信号后将培养瓶取出，将菌液分别接种于麦康凯琼脂培养基和血琼脂平板培养基上，于CO<sub>2</sub>培养箱(37℃, 6% &#177; 1%)中培养48小时后取优势菌落进行细菌的培养鉴定和药敏试验。其中细菌鉴定采用 VITEK2-Compact 全自动微生物分析系统(法国生物梅里埃公司)。药敏试验采用Kirby-Bauer扩散法，按照美国国家和临床实验室标准化协会(Clinicaland laboratory standarda institute, CLSI) 2018年标准判读 [<xref ref-type="bibr" rid="hanspub.36493-ref6">6</xref>]。药敏结果分为三种情况，分别为敏感(S)、中介(I)、耐药(R)。敏感率 = 敏感菌株数/该菌检测总株数 &#215; 100%，耐药率 = 耐药菌株数/该菌检测总株数 &#215; 100%。</p></sec><sec id="s4_4"><title>2.4. 统计学分析</title><p>应用SPSS 25.0软件录入数据，对所有数据进行描述性统计分析，计数资料采用株数(n)和百分率(%)表示。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 细菌培养结果</title><p>60例支架阻塞物培养结果均为阳性，试验共培养出93株病原菌，其中革兰阴性菌为61例，所占比例为65.6%；革兰阳性菌为30例，所占比例为32.2%；真菌为2例，所占比例为2.2%。排列前五位细菌的构成比由高到低依次为大肠埃希菌21例(22.6%)、屎肠球菌15例(16.1%)、肺炎克雷伯菌13例(14.0%)、铜绿假单胞菌11例(11.8%)、粪肠球菌10例(10.8%) (见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Species and distribution of pathogens causing obstruction of biliary plastic stent in 60 case</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >病原菌</th><th align="center" valign="middle" >株数(n)</th><th align="center" valign="middle" >构成比(%)</th></tr></thead><tr><td align="center" valign="middle" >革兰阴性杆菌</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >65.6</td></tr><tr><td align="center" valign="middle" >大肠埃希菌</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >22.6</td></tr><tr><td align="center" valign="middle" >肺炎克雷伯菌</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >14.0</td></tr><tr><td align="center" valign="middle" >铜绿假单胞菌</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >11.8</td></tr><tr><td align="center" valign="middle" >阴沟肠杆菌</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.4</td></tr><tr><td align="center" valign="middle" >鲍曼不动杆菌</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.2</td></tr><tr><td align="center" valign="middle" >普通变形杆菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >产气肠杆菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >嗜麦芽黄单胞菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >豚鼠气单胞菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >嗜麦芽黄单胞菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >木糖氧化产硷杆菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >革兰阳性球菌</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >32.2</td></tr><tr><td align="center" valign="middle" >屎肠球菌</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >16.1</td></tr><tr><td align="center" valign="middle" >粪肠球菌</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10.8</td></tr><tr><td align="center" valign="middle" >表皮葡萄球菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >变形链球菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.1</td></tr><tr><td align="center" valign="middle" >鸟肠球菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >真菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.2</td></tr><tr><td align="center" valign="middle" >光滑念珠菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >白色念珠菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >100.0</td></tr></tbody></table></table-wrap><p>表1. 60例胆道塑料支架阻塞物病原菌种类及分布</p></sec><sec id="s5_2"><title>3.2. 药敏结果分析</title><p>大肠埃希菌耐药率较高的抗菌药物从高到低依次为氨苄西林舒巴坦(57.7%)、左氧氟沙星(42.1%)、哌拉西林/他唑巴坦(36.5%)。敏感率较高的依次为美罗培南(100.0%)、亚胺培南(94.2%)、头孢哌酮舒巴坦(71.7%)。肺炎克雷伯菌对亚胺培南的敏感性达到100%，耐药率较高的为环丙沙星及阿米卡星，耐药率分别为45.5%、43.4%。铜绿假单胞菌对哌拉西林他唑巴坦、阿米卡星及左氧氟沙星耐药率均为45%左右。三种革兰阴性菌对美罗培南敏感率均达到100%，大肠埃希菌及铜绿假单胞菌虽然存在对亚胺培南的耐药菌株，但是敏感性仍较好，在88%以上(见表2)。</p><p>屎肠球菌、粪肠球菌耐药率相对较高的分别为庆大霉素54% vs 41.2%、红霉素52.7% vs 47.2%，屎肠球菌和粪肠球菌对亚胺培南、替考拉宁及利奈唑胺敏感率均达到100% (见表3)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Antimicrobial susceptibility result of three gram-negative bacteri</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >抗菌药物</th><th align="center" valign="middle"  colspan="2"  >大肠埃希菌(n = 21)</th><th align="center" valign="middle"  colspan="2"  >肺炎克雷伯菌(n = 13)</th><th align="center" valign="middle"  colspan="2"  >铜绿假单胞菌(n = 11)</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >耐药率(%)</td><td align="center" valign="middle" >敏感率(%)</td><td align="center" valign="middle" >耐药率(%)</td><td align="center" valign="middle" >敏感率(%)</td><td align="center" valign="middle" >耐药率(%)</td><td align="center" valign="middle" >敏感率(%)</td></tr><tr><td align="center" valign="middle" >头孢哌酮舒巴坦</td><td align="center" valign="middle" >28.3</td><td align="center" valign="middle" >71.7</td><td align="center" valign="middle" >26.9</td><td align="center" valign="middle" >73.1</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >63.5</td></tr><tr><td align="center" valign="middle" >氨苄西林/舒巴坦</td><td align="center" valign="middle" >57.7</td><td align="center" valign="middle" >42.3</td><td align="center" valign="middle" >33.1</td><td align="center" valign="middle" >65.7</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >哌拉西林/他唑巴坦</td><td align="center" valign="middle" >36.5</td><td align="center" valign="middle" >63.5</td><td align="center" valign="middle" >32.0</td><td align="center" valign="middle" >64.2</td><td align="center" valign="middle" >44.5</td><td align="center" valign="middle" >55.5</td></tr><tr><td align="center" valign="middle" >头孢他啶</td><td align="center" valign="middle" >28.4</td><td align="center" valign="middle" >71.6</td><td align="center" valign="middle" >34.5</td><td align="center" valign="middle" >65.5</td><td align="center" valign="middle" >30.0</td><td align="center" valign="middle" >70.0</td></tr><tr><td align="center" valign="middle" >亚胺培南</td><td align="center" valign="middle" >5.8</td><td align="center" valign="middle" >94.2</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >11.4</td><td align="center" valign="middle" >88.6</td></tr><tr><td align="center" valign="middle" >美罗培南</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >庆大霉素</td><td align="center" valign="middle" >28.9</td><td align="center" valign="middle" >71.1</td><td align="center" valign="middle" >28.1</td><td align="center" valign="middle" >70.4</td><td align="center" valign="middle" >38.5</td><td align="center" valign="middle" >61.5</td></tr><tr><td align="center" valign="middle" >阿米卡星</td><td align="center" valign="middle" >22.3</td><td align="center" valign="middle" >77.7</td><td align="center" valign="middle" >43.4</td><td align="center" valign="middle" >56.6</td><td align="center" valign="middle" >44.0</td><td align="center" valign="middle" >50.0</td></tr><tr><td align="center" valign="middle" >环丙沙星</td><td align="center" valign="middle" >33.1</td><td align="center" valign="middle" >66.9</td><td align="center" valign="middle" >45.5</td><td align="center" valign="middle" >54.5</td><td align="center" valign="middle" >36.4</td><td align="center" valign="middle" >63.6</td></tr><tr><td align="center" valign="middle" >左氧氟沙星</td><td align="center" valign="middle" >42.1</td><td align="center" valign="middle" >52.0</td><td align="center" valign="middle" >28.3</td><td align="center" valign="middle" >71.7</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >39.5</td></tr></tbody></table></table-wrap><p>表2. 3种革兰阴性杆菌对常用抗菌药物的药敏情况</p><p>-：表示未做该抗菌药物敏感试验；表中中介未列出。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Antimicrobial susceptibility result of two species of Enterococcu</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >抗菌药物</th><th align="center" valign="middle"  colspan="2"  >屎肠球菌(n = 15)</th><th align="center" valign="middle"  colspan="2"  >粪肠球菌(n = 10)</th></tr></thead><tr><td align="center" valign="middle" >耐药率(%)</td><td align="center" valign="middle" >敏感率(%)</td><td align="center" valign="middle" >耐药率(%)</td><td align="center" valign="middle" >敏感率(%)</td></tr><tr><td align="center" valign="middle" >氨苄西林</td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" >60.0</td><td align="center" valign="middle" >26.5</td><td align="center" valign="middle" >73.5</td></tr><tr><td align="center" valign="middle" >亚胺培南</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td></tr><tr><td align="center" valign="middle" >阿米卡星</td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" >45.8</td><td align="center" valign="middle" >41.2</td><td align="center" valign="middle" >58.8</td></tr><tr><td align="center" valign="middle" >庆大霉素</td><td align="center" valign="middle" >54.0</td><td align="center" valign="middle" >34.3</td><td align="center" valign="middle" >41.2</td><td align="center" valign="middle" >58.8</td></tr><tr><td align="center" valign="middle" >替考拉宁</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td></tr><tr><td align="center" valign="middle" >万古霉素</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >10.5</td><td align="center" valign="middle" >89.5</td></tr><tr><td align="center" valign="middle" >利奈唑胺</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td><td align="center" valign="middle" >0.0</td><td align="center" valign="middle" >100.0</td></tr><tr><td align="center" valign="middle" >红霉素</td><td align="center" valign="middle" >52.7</td><td align="center" valign="middle" >47.3</td><td align="center" valign="middle" >47.2</td><td align="center" valign="middle" >52.8</td></tr><tr><td align="center" valign="middle" >环丙沙星</td><td align="center" valign="middle" >36.3</td><td align="center" valign="middle" >63.7</td><td align="center" valign="middle" >26.4</td><td align="center" valign="middle" >58.2</td></tr><tr><td align="center" valign="middle" >莫西沙星</td><td align="center" valign="middle" >25.8</td><td align="center" valign="middle" >54.2</td><td align="center" valign="middle" >21.7</td><td align="center" valign="middle" >78.3</td></tr><tr><td align="center" valign="middle" >呋喃妥因</td><td align="center" valign="middle" >38.0</td><td align="center" valign="middle" >62.0</td><td align="center" valign="middle" >26.6</td><td align="center" valign="middle" >73.4</td></tr></tbody></table></table-wrap><p>表3. 2种肠球菌对常用抗菌药物的药敏情况</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>临床上对于恶性胆道梗阻的治疗，过去主要行外科手术，然而对于老年患者，恶病质患者，其创伤性较大，并发症较多，由于恶性胆道梗阻这一类疾病起病隐匿，早期缺乏特异症状，一般在发现时往往已经错失了最佳的手术时机 [<xref ref-type="bibr" rid="hanspub.36493-ref7">7</xref>]。因此，采取积极有效的措施缓解胆道梗阻是延长患者生存时间、提高患者生活质量的关键。在恶性胆道梗阻的诊断方面，ERCP的准确率可达80%以上 [<xref ref-type="bibr" rid="hanspub.36493-ref8">8</xref>]。近些年来，经ERCP置入胆道支架已经成为一种姑息性减压的行之有效的方法，特别适用于老年人 [<xref ref-type="bibr" rid="hanspub.36493-ref9">9</xref>]。本研究通过分析塑料支架阻塞物内腔中病原菌的种类及药敏试验，对临床上治疗胆系感染选用合适的抗生素具有重要意义。在本研究中，支架阻塞物细菌培养结果中最常见的细菌为革兰阴性菌，约为65.6%，革兰阳性菌约为32.2%，真菌检出率低，约为2.2%。排列前五位细菌的构成比由高到低依次为大肠埃希菌(22.6%)、屎肠球菌(16.1%)、肺炎克雷伯菌(14.0%)、铜绿假单胞菌(11.8%)、粪肠球菌(10.8%)。既往国外研究表明肠杆菌科(大肠杆菌和肺炎克雷伯菌)和肠球菌(屎肠球菌和粪肠球菌)是引起胆道感染的常见致病菌 [<xref ref-type="bibr" rid="hanspub.36493-ref10">10</xref>]。本研究中检出率较高的细菌仍以革兰阴性菌为主(65.6%)，这与ERCP术后获得的胆汁培养革兰阴性菌检出率较高相一致，胆道梗阻降低了胆道的抵抗力，致使肠道菌群从肠道移位到胆道 [<xref ref-type="bibr" rid="hanspub.36493-ref11">11</xref>]。另外，在外科手术中使用的医疗器械破坏了Oddi括约肌防逆流的保护机制，细菌大量进入胆道也容易引起胆道感染 [<xref ref-type="bibr" rid="hanspub.36493-ref12">12</xref>]。革兰阳性菌中肠球菌的检出率较高，与既往文献报道的结果相似 [<xref ref-type="bibr" rid="hanspub.36493-ref13">13</xref>]，Weber等人 [<xref ref-type="bibr" rid="hanspub.36493-ref14">14</xref>] 进行的一项研究发现在支架相关性胆管炎患者中肠球菌是最常见的一种，其检出率可超过70%。屎肠球菌和粪肠球菌为人类肠道的正常栖居菌，与胆道肠球菌感染相关的危险因素有既往胆道手术史、胰腺癌、胆结石、既往ERCP操作和入院时APACHEⅡ评分等 [<xref ref-type="bibr" rid="hanspub.36493-ref15">15</xref>]。铜绿假单胞菌是一种常见的革兰阴性机会致病菌，人体免疫力低下时极易成为致病菌群，且容易产生耐药，恶性胆道梗阻患者中铜绿假胞菌的检出则可能与患者放置过胆道支架以及T管引流等操作有关 [<xref ref-type="bibr" rid="hanspub.36493-ref16">16</xref>]。真菌检出率相对较低为2.2%，真菌属于条件致病菌，长期不合理应用广谱抗菌药物以及侵入性操作会增加胆道感染合并医院内真菌感染的机率 [<xref ref-type="bibr" rid="hanspub.36493-ref17">17</xref>]。由于大部分胆系感染患者多以需氧菌感染的情况多见 [<xref ref-type="bibr" rid="hanspub.36493-ref18">18</xref>]，以及本研究的试验条件限制，未检测厌氧菌。我们发现国内外研究中各种细菌检出的比例存在一定的差异，这可能与取材部位、支架取出后进行微生物学分析的时间间隔不同等相关 [<xref ref-type="bibr" rid="hanspub.36493-ref19">19</xref>]。</p><p>在本研究分离出的革兰阴性菌中，三种主要革兰阴性菌均对美罗培南(100%)、亚胺培南(88%~100%)保持着较高的敏感性，其他相对敏感的抗菌药物包括头孢哌酮舒巴坦、头孢他啶、庆大霉素、哌拉西林他唑巴坦以及环丙沙星等。其中大肠埃希菌及铜绿假单胞菌存在对亚胺培南的耐药株，但是敏感性仍在88%以上。两种肠球菌敏感率可达到100%的抗菌药为亚胺培南、替考拉宁、利奈唑胺。我们在临床上发现初始抗生素覆盖不足是导致胆系感染的一个危险因素，目前临床上对于抗生素的选择往往是经验性用药，其中考虑了医院获得性感染、既往肝胆外科手术史、患者的个人体质情况及当地的耐药情况 [<xref ref-type="bibr" rid="hanspub.36493-ref11">11</xref>]。其中碳氢霉烯类药物是对革兰阴性菌及革兰阳性菌均敏感有效的抗菌药，针对一些重症患者可首选碳氢霉烯类药物，且注意使用时间不宜超过1周，病情好转之后再根据细菌培养和药敏结果调整抗生素 [<xref ref-type="bibr" rid="hanspub.36493-ref10">10</xref>]。革兰阴性杆菌对氨基糖苷类抗生素也保持着较高的敏感性，但由于存在耳毒性和肾毒性的风险，应当谨慎用药 [<xref ref-type="bibr" rid="hanspub.36493-ref20">20</xref>]，尤其是对于老年患者，更应该注意药物的毒副作用。据报道，喹诺酮类药物环丙沙星治疗胆系感染效果比较好，其在胆汁中的药物浓度为血清浓度的3~10倍 [<xref ref-type="bibr" rid="hanspub.36493-ref21">21</xref>]。然而在本研究中，检出率较高的前五位细菌对环丙沙星的敏感率为54%~67%，故我们不建议不单独使用该药，必要时联合用药以有效的控制感染。</p><p>胆道支架的狭窄阻塞会引起胆系感染反复发生，我们建议当胆系感染控制的情况下应及时尽早的更换支架。根据现有的研究，塑料支架的平均通畅时间在70到126天之间 [<xref ref-type="bibr" rid="hanspub.36493-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.36493-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.36493-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.36493-ref25">25</xref>]。因此，大多数内窥镜检查以3个月的时间间隔进行支架交换，以避免支架阻塞 [<xref ref-type="bibr" rid="hanspub.36493-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.36493-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.36493-ref26">26</xref>]。本研究中因胆系感染更换支架的患者比例已经约为68.3%，建议患者在无禁忌的情况提前更换支架，可能会降低梗阻性黄疸及胆系感染并发症的发生。</p><p>综上，对于老年恶性胆道梗阻患者，塑料支架内腔阻塞物病原菌培养阳性率高，革兰阴性菌为主要的病原菌，构成比排名前五位的细菌由高到低依次为大肠埃希菌、屎肠球菌、肺炎克雷伯菌、铜绿假单胞菌、粪肠球菌。因此，临床上经验性选择抗菌药物时，建议最好覆盖革兰阴性杆菌及肠球菌属类敏感的抗菌药物，并根据药敏结果进一步调整用药；早期积极应用碳青霉烯类药物可以有效控制感染。无禁忌的情况下，应该及时更换支架，以便解除胆道梗阻。同时本研究也存在一定的局限性，我们纳入的病例数过少，未来需要多中心、大样本的数据进一步验证，并且在ERCP取支架的过程中可能存在污染，要求术者操作熟练并且必须注意无菌操作。</p></sec><sec id="s7"><title>文章引用</title><p>孔国萍,解祥军. 老年恶性胆道梗阻患者塑料支架阻塞物细菌学和抗生素耐药性分析Analysis of Bacteriology and Antibiotic Resistance of Plastic Stent Obstruction in Elderly Patients with Malignant Biliary Obstruction[J]. 临床医学进展, 2020, 10(07): 1298-1305. https://doi.org/10.12677/ACM.2020.107197</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36493-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Lorenz, J.M. (2016) Management of Malignant Biliary Obstruction. Seminars in Interventional Radiology, 33, 259-267.  
&lt;br&gt;https://doi.org/10.1055/s-0036-1592330</mixed-citation></ref><ref id="hanspub.36493-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hucl, T. (2016) [Malignant Biliary Obstruction]. Casopis Lékaru Ceských, 155, 30-37.</mixed-citation></ref><ref id="hanspub.36493-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">李子祥. 胆道支架的选择与临床应用[J]. 中华介入放射学电子杂志, 2019, 7(1): 7-16.</mixed-citation></ref><ref id="hanspub.36493-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Vaishnavi, C., Samanta, J. and Kochhar, R. (2018) Characterization of Biofilms in Biliary Stents and Potential Factors Involved in Occlusion. World Journal of Gastroenterology, 24, 112-123. &lt;br&gt;https://doi.org/10.3748/wjg.v24.i1.112</mixed-citation></ref><ref id="hanspub.36493-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Guo, Y., Liu, Y., Lu, Z., et al. (2014) Obstructive Component Analysis of Radioactive Stents and Common Plastic Stents in the Bile Duct. European Journal of Gastroenterology &amp; Hepatology, 26, 795-802.  
&lt;br&gt;https://doi.org/10.1097/MEG.0000000000000120</mixed-citation></ref><ref id="hanspub.36493-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Clinical and Laboratory Standards Institute (CLSI) (2018) Performance Standards for Antimicrobial Susceptibility Testing. CLSI Document M100: 2018, CLSI, Wayne, PA.</mixed-citation></ref><ref id="hanspub.36493-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">邹茂贤, 唐兴奎, 何金花, 等. 恶性胆道梗阻患者行ERCP支架置入治疗的效果及其肝功能指标的变化[J]. 检验医学与临床, 2018, 15(13): 1948-1951.</mixed-citation></ref><ref id="hanspub.36493-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">梁君蓉, 石德红, 张冲, 等. ERCP胆管支架置入与传统手术方法解除恶性胆道梗阻的临床疗效及安全性比较[J]. 实用癌症杂志, 2015, 30(2): 311-313.</mixed-citation></ref><ref id="hanspub.36493-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">刘加宁, 朱美玲, 张子久. 自膨式金属支架置入术在晚期胆道恶性梗阻治疗中的应用[J]. 中国医药, 2012, 7(1): 76-78.</mixed-citation></ref><ref id="hanspub.36493-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kwon, J.S., Han, J., Kim, T.W., et al. (2014) Changes in Causative Pathogens of Acute Cholangitis and Their Antimicrobial Susceptibility over a Period of 6 Years. The Korean Journal of Gastroenterology, 63, 299-307.  
&lt;br&gt;https://doi.org/10.4166/kjg.2014.63.5.299</mixed-citation></ref><ref id="hanspub.36493-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chandra, S., Klair, J.S., Soota, K., et al. (2019) Endoscopic Retrograde Cholangio-Pancreatography-Obtained Bile Culture Can Guide Antibiotic Therapy in Acute Cholangitis. Digestive Diseases, 37, 155-160.  
&lt;br&gt;https://doi.org/10.1159/000493579</mixed-citation></ref><ref id="hanspub.36493-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">于犇犇, 汪璐璐, 吴若林, 等. 348例肝胆疾病患者胆汁病原菌构成及耐药性分析[J]. 肝胆外科杂志, 2018, 26(5): 344-347.</mixed-citation></ref><ref id="hanspub.36493-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lubbert, C., Wendt, K., Feisthammel, J., et al. (2016) Epidemiology and Resistance Patterns of Bacterial and Fungal Colonization of Biliary Plastic Stents: A Prospective Cohort Study. PLoS ONE, 11, e155479.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0155479</mixed-citation></ref><ref id="hanspub.36493-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Weber, A., Schneider, J., Wagenpfeil, S., et al. (2013) Spectrum of Pathogens in Acute Cholangitis in Patients with and without Biliary Endoprosthesis. Journal of Infection, 67, 111-121. &lt;br&gt;https://doi.org/10.1016/j.jinf.2013.04.008</mixed-citation></ref><ref id="hanspub.36493-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">官旭, 毛丽芬, 任建敏. 胆道肠球菌感染的相关危险因素与耐药性比较分析[J]. 中国卫生检验杂志, 2018, 28(1): 53-55, 67.</mixed-citation></ref><ref id="hanspub.36493-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">孟珂, 孙兰菊, 崔云峰, 等. 胆道手术者胆汁细菌学和抗生素耐药性研究[J]. 中国卫生检验杂志, 2017, 27(11): 1661-1664.</mixed-citation></ref><ref id="hanspub.36493-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">张健, 刘鸿亚, 袁克文, 等. 某院113例胆道感染患者胆汁病原菌分布及耐药谱描述[J]. 中国校医, 2019, 33(1): 36-38.</mixed-citation></ref><ref id="hanspub.36493-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Westphal, J.F. and Brogard, J.M. (1999) Biliary tract Infections: A Guide to Drug Treatment. Drugs, 57, 81-91.  
&lt;br&gt;https://doi.org/10.2165/00003495-199957010-00007</mixed-citation></ref><ref id="hanspub.36493-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">迟海本. 塑料胆道支架梗阻的因素和预防措施[J]. 海南医学, 2014, 25(5): 706-708.</mixed-citation></ref><ref id="hanspub.36493-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">邓海锐. 氨基糖苷类抗生素: 结构、作用模式和抗性机制[J]. 饮食保健, 2018, 5(28): 83-85.</mixed-citation></ref><ref id="hanspub.36493-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">李震, 常保生, 将德安. 环丙沙星治疗胆道疾病临床观察[J]. 西北药学杂志, 2000, 15(4): 193.</mixed-citation></ref><ref id="hanspub.36493-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Schneider, J., Hapfelmeier, A., Fremd, J., et al. (2014) Biliary Endoprosthesis: A Prospective Analysis of Bacterial Colonization and Risk Factors for Sludge Formation. PLoS ONE, 9, e110112.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0110112</mixed-citation></ref><ref id="hanspub.36493-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Dumonceau, J.M., Tringali, A., Blero, D., et al. (2012) Biliary Stenting: Indications, Choice of Stents and Results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy, 44, 277-298.  
&lt;br&gt;https://doi.org/10.1055/s-0031-1291633</mixed-citation></ref><ref id="hanspub.36493-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Baron, T.H.S. and DaVee, T. (2013) Endoscopic Management of Benign Bile Duct Strictures. Gastrointestinal Endoscopy Clinics of North America, 23, 295-311. &lt;br&gt;https://doi.org/10.1016/j.giec.2013.01.001</mixed-citation></ref><ref id="hanspub.36493-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lawrence, C., Romagnuolo, J., Payne, K.M., et al. (2010) Low Symptomatic Premature Stent Occlusion of Multiple Plastic Stents for Benign Biliary Strictures: Comparing Standard and Prolonged Stent Change Intervals. Gastrointestinal Endoscopy, 72, 558-563. &lt;br&gt;https://doi.org/10.1016/j.gie.2010.05.029</mixed-citation></ref><ref id="hanspub.36493-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">van Berkel, A.M., Boland, C., Redekop, W.K., et al. (1998) A Prospective Randomized Trial of Teflon versus Polyethylene Stents for Distal Malignant Biliary Obstruction. Endoscopy, 30, 681-686.  
&lt;br&gt;https://doi.org/10.1055/s-2007-1001388</mixed-citation></ref></ref-list></back></article>